Abu Dhabi Promotes Precision Treatment for Alzheimer’s Patients
- Healthcare and General Service
- July 3, 2025
Highlights
- Abu Dhabi has integrated APOE genetic testing for Alzheimer’s disease into its pharmacogenomics reports, enabling personalised treatments and safer care
- The Department of Health, Abu Dhabi and M42’s Biogenix Lab are committed to regularly updating pharmacogenomics tools to keep up with scientific advancements
The Department of Health (DoH), Abu Dhabi, and M42’s Biogenix Lab have partnered to include apolipoprotein (APOE) E4 genotyping in pharmacogenomics reports, marking a milestone in precision medicine. This will help clinicians tailor Alzheimer’s treatment plans for individuals with two copies of APOE E4 and help prevent severe side effects.
Dr. Fahed Al Marzooqi, CEO of M42, has announced the integration of pharmacogenomics into Abu Dhabi’s clinical care. The initiative is led by the Department of Health and supported by M42’s advanced health technology infrastructure.
Dr. Asma Al Mannaei, Executive Director of the Health Life Sciences Sector at the DoH, Abu Dhabi, highlighted the inclusion of APOE E4 genotyping in the PGx report as part of their commitment to providing best-in- class care through genetic profiling and precision therapies
PGx reports help healthcare providers customise treatments based on body metabolism type and drug effects. The reports incorporate pharmacogenomics insights, covering 22 pharmacogenes and 183 medications, allowing for optimised drug selection, reduced adverse reactions, and improved therapeutic outcomes.
The Emirati Genome Programme (EGP) has made 160,000 pharmacogenomics reports available to all physicians in Abu Dhabi through Malaffi, the DoH’s health information exchange. This achievement sets a new standard for population genomics, surpassing many global applications and enhancing tailored treatments for EGP participants.
